CN116158403A - SARS-CoV-2包膜蛋白诱导的肾纤维化模型的建立 - Google Patents
SARS-CoV-2包膜蛋白诱导的肾纤维化模型的建立 Download PDFInfo
- Publication number
- CN116158403A CN116158403A CN202310191281.2A CN202310191281A CN116158403A CN 116158403 A CN116158403 A CN 116158403A CN 202310191281 A CN202310191281 A CN 202310191281A CN 116158403 A CN116158403 A CN 116158403A
- Authority
- CN
- China
- Prior art keywords
- cov
- sars
- envelope protein
- establishment
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000667982 Severe acute respiratory syndrome coronavirus 2 Envelope small membrane protein Proteins 0.000 title claims abstract description 22
- 206010023421 Kidney fibrosis Diseases 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 12
- 201000002793 renal fibrosis Diseases 0.000 claims abstract description 9
- 101710091045 Envelope protein Proteins 0.000 claims description 22
- 101710188315 Protein X Proteins 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 14
- 238000010171 animal model Methods 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 229920000936 Agarose Polymers 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 230000009465 prokaryotic expression Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000002158 endotoxin Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 241001678559 COVID-19 virus Species 0.000 abstract description 18
- 230000007705 epithelial mesenchymal transition Effects 0.000 abstract description 11
- 210000003734 kidney Anatomy 0.000 abstract description 11
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 230000007246 mechanism Effects 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 26
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102000057208 Smad2 Human genes 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 102000013127 Vimentin Human genes 0.000 description 4
- 108010065472 Vimentin Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 210000005048 vimentin Anatomy 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 238000000035 BCA protein assay Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000024715 positive regulation of secretion Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002782 epithelial mesenchymal cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000001804 kidney proximal tubule epithelial cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明属于生物技术领域,涉及SARS‑CoV‑2包膜蛋白诱导的肾纤维化模型的建立。具体包括一种SARS‑CoV‑2包膜蛋白诱导的小鼠肾纤维化模型的建立以及一种SARS‑CoV‑2包膜蛋白诱导的HK‑2细胞上皮间充质转化模型的建立。本发明首次公开了SARS‑CoV‑2包膜蛋白诱导的肾纤维化模型的建立方法,解决了现有的SARS‑CoV‑2直接感染模型建立方法中成本高、操作条件严苛等问题,为进一步深入研究SARS‑CoV‑2相关的肾脏病理机制以及筛选相关药物提供了新的实验途径。
Description
技术领域
本发明属于生物技术领域,涉及一种SARS-CoV-2包膜蛋白诱导的肾纤维化模型的建立,具体为一种SARS-CoV-2包膜蛋白诱导的小鼠肾纤维化模型的建立以及一种SARS-CoV-2包膜蛋白诱导的HK-2细胞上皮间充质转化模型的建立。
背景技术
新型冠状病毒(Severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)严重危害到了人类健康。SARS-CoV-2除了侵害呼吸系统,还会损害全身多种器官。其中,肾脏就是主要受损器官之一。SARS-CoV-2能够直接感染肾细胞,感染后的肾脏主要表现为肾小管损伤,并在患者尸检样本发现肾小管间质纤维化相关指标显著增加。临床上,SARS-CoV-2感染者的肾脏损害,不仅会增加治疗和护理的难度,还会增加患有潜在肾脏疾病的人的死亡率。一种SARS-CoV-2相关的肾纤维化模型对于SARS-CoV-2的深入研究有着重要的意义。然而,SARS-CoV-2直接感染模型的建立有着以下两个难点:(1)SARS-CoV-2无法感染啮齿类动物,需要用到人源化的小鼠,模型成本大幅增高;(2)SARS-CoV-2需要在生物安全3级的实验室操作,操作要求严苛,大部分实验室无法实现。于是,建立一种与SARS-CoV-2直接感染类似的肾纤维化动物模型意义重大。动物的脏器纤维化对应于细胞层面就是上皮间充质转化,上皮细胞由一系列病理因素导致的向间充质细胞的转化是纤维化发生的基础。所以,在细胞层面建立一种与SARS-CoV-2直接感染类似的上皮间充质转化模型同样具有重大的意义。
发明内容
本发明的目的是提供一种SARS-CoV-2包膜蛋白诱导的小鼠肾纤维化模型的建立以及一种SARS-CoV-2包膜蛋白诱导的HK-2细胞上皮间充质转化模型的建立,解决了现有的SARS-CoV-2直接感染模型建立方法中成本高、操作条件严苛等问题。
为解决上述技术问题,本发明采用的技术方案如下:
本发明第一个方面公开了SARS-CoV-2包膜蛋白在诱导肾纤维化模型建立的应用。
其中,所述SARS-CoV-2包膜蛋白需通过pET28a-SARS-CoV-2-E-6×His质粒原核表达系统纯化提取。
优选地,所述原核表达系统为大肠杆菌E.coli BL21 DE3 pLysS表达体系。
具体地,22℃下用0.5mM异丙基-b-D-1-硫代吡喃半乳糖苷诱导SARS-CoV-2蛋白质表达16-18小时,随后纯化获得SARS-CoV-2包膜蛋白。
优选地,所述纯化的具体方法为:使用Ni-NTA树脂分离6×His包膜蛋白并用内毒素去除琼脂糖树脂去除内毒素。
肾纤维化模型包括动物模型和细胞模型:
其中动物模型,使用啮齿类动物,如小鼠,将纯化的包膜蛋白通过尾静脉注射入小鼠体内(25mg·kg-1),一次注射,期间收集尿液检测尿肌酐和尿蛋白水平,监测肾功能,约4周后出现明显肾纤维化,得到肾纤维化动物模型;
优选的,本发明中动物模型建立使用野生型小鼠即可。
优选的,本发明中动物模型建立只需要尾静脉注射一次。
优选的,本发明中动物模型建立只需要4周时间。
其中细胞模型,使用人肾小管上皮细胞——HK-2细胞系,HK-2细胞无血清饥饿12小时后,将纯化的包膜蛋白(2μg/mL)加入HK-2细胞培养基中继续培养24小时,HK-2细胞出现明显上皮间充质转化,得到肾纤维化细胞模型。
优选的,本发明中细胞模型建立只需要加诱导物一次,无其他特殊操作。
本发明所建立的细胞模型,上皮间充质转化相关指标显著上调。
与现有技术相比,本发明有如下优势:
本发明的技术方案表明了包膜(Envelope,E)蛋白作为SARS-CoV-2的主要结构蛋白之一,其能够作为一种独立的毒力因子引起炎症和多器官损伤。而且包膜蛋白所诱导的损伤类型与SARS-CoV-2直接感染引起的损伤高度相似,能够很好地代替研究SARS-CoV-2相关的病理过程。
本发明进一步提供了一种利用SARS-CoV-2的一个结构蛋白——包膜蛋白直接感染的肾纤维化动物及细胞模型建立方法。
附图说明
图1.包膜蛋白对小鼠肾功能和体重的影响:
(A)动物造模的示意图:Mock组(n=6),小鼠尾静脉注射与纯化蛋白等体积的TBS(纯化蛋白洗脱液);E Protein组(n=6),小鼠尾静脉注射包膜蛋白(25mg·kg-1体重);(B)肾功能评估(n=6),蛋白尿通过尿蛋白与肌酐的比值进行定量;(C)实验期间小鼠体重变化(n=6)。
图2.包膜蛋白对小鼠肾脏病理结构的影响:
(A)代表性的肾脏病理损伤图;(B)代表性的肾脏苏木精-伊红染色(H&E)图像(比例尺=50μm)。
图3.包膜蛋白诱导小鼠肾脏纤维化:
(A)包膜蛋白对肾脏纤维化指标(fibronectin(FN),vimentin,和α-smoothmuscle actin(α-SMA))蛋白表达的影响;(B)蛋白表达水平的定量分析;(C)包膜蛋白对纤维化指标(fibronectin(FN),vimentin,和α--smooth muscle actin(α-SMA))mRNA水平的影响;(D)代表性的肾脏Masson三色染色图像(比例尺=50μm)。所有值均为平均值±SD;单向方差分析。**P<0.01,***P<0.001,(n=6)。
图4.包膜蛋白诱导HK-2细胞上皮间充质转化:
(A)包膜蛋白对细胞上皮间充质转化指标(fibronectin(FN),vimentin,和α-smooth muscle actin(α-SMA))蛋白表达的影响;(B)蛋白表达水平的定量分析。所有值均为平均值±SD;单向方差分析。ns P>0.05,*P<0.05,***P<0.001,(n=5)。
图5.包膜蛋白通过刺激小鼠肾脏TGF-β1的分泌激活TGF-β1/Smad2/3通路:
(A)小鼠血清中TGF-β1的水平。(B)包膜蛋白对肾脏TGF-β1/Smad2/3通路的激活情况的影响。(C)蛋白表达水平的定量分析。所有值均为平均值±SD;单向方差分析。***P<0.001,(n=6)。
图6.包膜蛋白通过刺激HK-2细胞TGF-β1的分泌激活TGF-β1/Smad2/3通路:
(A)HK-2细胞培养上清中TGF-β1的水平。(B)包膜蛋白对HK-2细胞TGF-β1/Smad2/3通路的激活情况的影响。(C)蛋白表达水平的定量分析。所有值均为平均值±SD;单向方差分析。***P<0.001,(n=5)。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。本发明所用试剂和原料均市售可得。
实施例1
本实施例公开了一种SARS-CoV-2包膜蛋白诱导的小鼠肾纤维化模型的建立方法,具体如下:
1、动物
C57BL/6小鼠,雄性,8周,购于上海灵畅实验动物有限公司,饲养于复旦大学药学院实验动物中心SPF级动物实验室。
2、实验材料
抗α-SMA(1:10000)和FN(1:1000)抗体购自Abcam。抗GAPDH(1:5000)、p-Smad23(1:10001)、Smad23和vimentin(1:1000)抗体购自Cell Signaling Technology(CST)。抗TGF-β1(1:1000)购自爱博泰克。
3、实验仪器
生物安全柜(Thermo Fisher),CO2细胞培养箱(Thermo Fisher)、冷冻离心机(Thermo Fisher)、微量移液器(Eppendorf)、恒温水浴锅(上海精宏实验设备有限公司)、凝胶电泳装置(Bio Rad)、转印装置(Bio Rad)、凝胶图像处理系统(BioRad)、倒置显微镜(Carl Zeiss)、Q-RTPCR仪(Bio-Rad)、组织匀浆仪(上海净信科技)、酶标仪(Tecan SystemsInc.)。
4、实验方法
(1)蛋白质纯化
诱导表达:将pET28a-SARS-CoV-2-E-6×His质粒转染到大肠杆菌E.coli BL21(DE3)pLysS(TransGen Biotech)中以表达融合蛋白。在50μg·mL-1卡那霉素的50mL LB培养基中开始扩增单个菌落,并在37℃下以220rpm振荡培养细胞。起始培养物接种至1LLB培养基中(含50μg·mL-1卡那霉素),37℃,220rpm振荡培养,直到600nm处的光密度(OD600)达到0.6-0.8。然后加入0.5mM IPTG(异丙基-b-D-1-硫代吡喃半乳糖苷;Yeasen),22℃,220rpm,诱导蛋白质表达16-18小时。
制备蛋白悬液:4℃,8000rpm离心20分钟收集细菌,并将其重新悬浮在结合缓冲液(150mMNaCl,20mM Tris-base,1mM DTT,1%PMSF,1×cocktail,pH 8.0)中。将重新悬浮的细菌在4℃下用超声仪裂解60分钟。通过在4℃下以10000g离心30分钟将细胞裂解物的可溶性部分与细胞碎片分离,并通过0.22μM过滤器过滤上清液以去除颗粒。
分离纯化:用TBS缓冲液(150mM NaCl,20mM Tris-base,pH 8.0)预平衡Ni-NTA树脂(Yeasen)。将澄清的上清液加载在5mLNi-NTA上4小时,以从大肠杆菌蛋白中分离E-6×His融合蛋白。分别用含20mM、30mM、50mM的咪唑浓度的TBS洗脱液,以10倍柱体积洗涤柱。洗涤后,用含300mM咪唑的TBS洗脱液洗脱E-6×His融合蛋白。然后使用用TBS预平衡的Superdex 75Increase 10/300凝胶过滤色谱(GE Healthcare)纯化E-6×His融合蛋白。最后,用内毒素去除琼脂糖树脂(Yeasen)去除内毒素。
浓缩:TBS平衡琼脂糖树脂后,将纯化的蛋白以0.25mL·min-1的速度加载到树脂上。使用离心过滤装置(Amicon@Ultra)收集洗脱液进行浓缩。
(2)SARS-CoV-2包膜蛋白诱导的小鼠肾纤维化模型的建立
将12只8周龄的雄性C57BL/6小鼠随机分为2组:对照组(n=6),尾静脉注射与纯化蛋白等体积的TBS(纯化蛋白洗脱液);包膜蛋白组(n=6),尾静脉注射纯化包膜蛋白(25mg·kg-1体重)
(3)肾功能评估
造模期间收集尿液样本,通过尿蛋白与肌酐的比值评估肾功能。通过尿蛋白检测试剂盒(中国南京建城生物工程研究所)测量尿蛋白含量。用肌酐测定试剂盒(中国南京建城生物工程研究所)测定肌酐含量。
(4)肾脏病理检测
将分离的小鼠肾脏组织并在室温下在10%福尔马林中固定48小时。固定组织包埋在石蜡中,并切成4μm厚的切片,进行苏木精-伊红染色(H&E)和Masson三色染色。
(5)细胞因子TGF-β1的检测
将小鼠血清在4℃下以1500g离心10min,收集上清液。小鼠血清中的细胞因子按照说明书使用ELISA试剂盒(Multi Science Biotech)进行测定。
(6)蛋白质表达检测
通过Western blotting分析肾脏中的蛋白质。用补充有1%混合蛋白酶抑制剂(Beyotime)的RIPA缓冲液在冰上裂解肾脏组织30分钟。通过12000g离心15分钟除去不溶性物质,并收集上清液。
使用BSA作为标准,用BCA蛋白质测定法(Beyotime)给蛋白定量。在样品蛋白中加入SDS-PAGE样品加载缓冲液(Beyotime),于95℃变性5~10分钟。通过SDS-PAGE分离各个分子量的蛋白,转膜至PVDF膜(Millipore),在室温下用TBST缓冲液(0.1%Tween-20和0.1MNaCl,0.1M Tris-HCl,pH 7.5)中的5%无脂牛奶封闭1小时,然后在4℃下与一抗孵育过夜。用TBST洗涤三次(每次10分钟)后,加入辣根过氧化物酶结合的二抗(1:5000;SantaCruz Biotechnology),并在室温下孵育1小时。通过使用图像分析系统(Quantity One软件;BioRad ChemidDoc,BioRad,USA)定量分析蛋白质带。
(7)mRNA检测
使用TRIzol试剂(Invitrogen)从肾脏中提取总RNA,并使用primeScriptRTMaster Mix(Takara)合成互补DNA。根据说明书,使用TB Green预混物Ex Taq(Takara)进行qRT PCR扩增。以GAPDH基因为内参,将结果归一化,并使用2-(ΔΔCt)公式计算变化倍数。
实验结果如图1、2、3、5所示:包膜蛋白能够损伤肾小管细胞,造成体重下降、蛋白尿以及明显肾纤维化,且诱导肾纤维化的相关机制可能是通过促进TGF-β1的分泌,从而激活了TGF-β1/Smad2/3通路。
实施例2
本实施例公开了一种SARS-CoV-2包膜蛋白诱导的HK-2细胞上皮间充质转化模型建立的方法。
实验方法如下:
(1)SARS-CoV-2包膜蛋白诱导的HK-2细胞上皮间充质转化模型的建立
HK-2(人肾近端小管上皮细胞)在RPMI1640培养基(Thermo Fisher Scientific)中培养,培养基中含有10%血清(Gibco)和100U·mL-1青霉素/链霉素(Gibco)。
将5×105HK-2细胞接种在具有完整培养基的6孔板中12小时。然后,在无血清的培养基中饥饿12-16小时。饥饿后,用纯化的包膜蛋白以一系列浓度(0.5、1、2μg/mL)刺激细胞24小时。
(2)细胞因子TGF-β1的检测
将细胞培养上清在4℃下以1500g离心10min,收集上清液。细胞因子按照说明书使用ELISA试剂盒(Multi Science Biotech)进行测定。
(6)蛋白质表达检测
通过Western blotting分析细胞中的蛋白质。用补充有1%混合蛋白酶抑制剂(Beyotime)的RIPA缓冲液在冰上裂解肾脏组织30分钟。通过12000g离心15分钟除去不溶性物质,并收集上清液。
使用BSA作为标准,用BCA蛋白质测定法(Beyotime)给蛋白定量。在样品蛋白中加入SDS-PAGE样品加载缓冲液(Beyotime),于95℃变性5~10分钟。通过SDS-PAGE分离各个分子量的蛋白,转膜至PVDF膜(Millipore),在室温下用TBST缓冲液(0.1%Tween-20和0.1MNaCl,0.1M Tris-HCl,pH 7.5)中的5%无脂牛奶封闭1小时,然后在4℃下与一抗孵育过夜。用TBST洗涤三次(每次10分钟)后,加入辣根过氧化物酶结合的二抗(1:5000;SantaCruz Biotechnology),并在室温下孵育1小时。通过使用图像分析系统(Quantity One软件;BioRad ChemidDoc,BioRad,USA)定量分析蛋白质带。
(7)mRNA检测
使用TRIzol试剂(Invitrogen)从细胞中提取总RNA,并使用primeScriptRTMaster Mix(Takara)合成互补DNA。根据说明书,使用TB Green预混物Ex Taq(Takara)进行qRT PCR扩增。以GAPDH基因为内参,将结果归一化,并使用2-(ΔΔCt)公式计算变化倍数。
实验结果如图4、6所示:包膜蛋白能够诱导HK-2细胞发生明显的上皮间充质转化,且诱导上皮间充质转化的相关机制可能是通过促进TGF-β1的分泌,从而激活了TGF-β1/Smad2/3通路。相关机制与动物模型相似。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (6)
1.SARS-CoV-2包膜蛋白在诱导肾纤维化模型建立的应用。
2.如权利要求1所述的SARS-CoV-2包膜蛋白的提取方法,其特征在于,所述SARS-CoV-2包膜蛋白需通过pET28a-SARS-CoV-2-E-6×His质粒原核表达系统纯化提取。
3.如权利要求2所述的方法,其特征在于,所述原核表达系统为大肠杆菌E.coliBL21DE3 pLysS表达体系。
4.如权利要求3所述的方法,其特征在于,22℃下用0.5mM异丙基-b-D-1-硫代吡喃半乳糖苷诱导SARS-CoV-2蛋白质表达16-18小时,随后纯化获得SARS-CoV-2包膜蛋白。
5.如权利要求4所述的方法,其特征在于,所述纯化的具体方法为:使用Ni-NTA树脂分离6×His包膜蛋白并用内毒素去除琼脂糖树脂去除内毒素。
6.如权利要求1所述的肾纤维化模型,其特征在于,包括动物模型和细胞模型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310191281.2A CN116158403A (zh) | 2023-03-02 | 2023-03-02 | SARS-CoV-2包膜蛋白诱导的肾纤维化模型的建立 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310191281.2A CN116158403A (zh) | 2023-03-02 | 2023-03-02 | SARS-CoV-2包膜蛋白诱导的肾纤维化模型的建立 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116158403A true CN116158403A (zh) | 2023-05-26 |
Family
ID=86416270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310191281.2A Pending CN116158403A (zh) | 2023-03-02 | 2023-03-02 | SARS-CoV-2包膜蛋白诱导的肾纤维化模型的建立 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116158403A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113475463A (zh) * | 2021-02-03 | 2021-10-08 | 湖州市中心医院 | 一种新型冠状病毒致肺损伤动物模型的建立方法及其小鼠模型 |
CN116251097A (zh) * | 2023-03-02 | 2023-06-13 | 复旦大学 | 奥美沙坦在治疗SARS-CoV-2包膜蛋白诱导的肾纤维化中的应用 |
-
2023
- 2023-03-02 CN CN202310191281.2A patent/CN116158403A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113475463A (zh) * | 2021-02-03 | 2021-10-08 | 湖州市中心医院 | 一种新型冠状病毒致肺损伤动物模型的建立方法及其小鼠模型 |
CN116251097A (zh) * | 2023-03-02 | 2023-06-13 | 复旦大学 | 奥美沙坦在治疗SARS-CoV-2包膜蛋白诱导的肾纤维化中的应用 |
Non-Patent Citations (1)
Title |
---|
刘洋等, 《解剖学杂志》, vol. 45, no. 2, 25 April 2022 (2022-04-25), pages 157 - 160 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050003529A1 (en) | Stem cells and method of separating the same | |
CN108929874B (zh) | 一种特异性结合高表达pdl1蛋白的细胞的核酸适配体及其应用 | |
CA2558515C (en) | Method of enriching and/or separating prokaryotic dna by means of a protein which specifically binds dna containing non-methylated cpg motifs | |
US20120129720A1 (en) | Aptamer that recognizes peptide | |
Almasia et al. | Successful production of the potato antimicrobial peptide Snakin-1 in baculovirus-infected insect cells and development of specific antibodies | |
CN103451187B (zh) | 重组中性粒细胞明胶酶相关脂质运载蛋白及该蛋白抗体的制备方法 | |
KR20170054262A (ko) | Socs가 억제된 면역억제능이 향상된 줄기세포 및 그의 이용 | |
CN117866902B (zh) | 具有抗il-17a活性的基因修饰干细胞及其制备方法以及药物组合物 | |
EP3527982A1 (en) | Method for selecting high-efficacy stem cell by using downregulation in expression or activity of socs | |
CN111979357A (zh) | 基于CRISPR-Cas13a的牛病毒性腹泻病毒的检测方法 | |
CN112472795B (zh) | 用于抑制细胞对炎性因子刺激的应答的生物制剂 | |
CN116158403A (zh) | SARS-CoV-2包膜蛋白诱导的肾纤维化模型的建立 | |
CN106279427A (zh) | 具有胶原特异结合能力的神经再生抑制分子的拮抗蛋白CBD-EphA4LBD及应用 | |
EP2514821B1 (en) | Cystatin C, antibody | |
Hauser et al. | Discovery of granulocyte-lineage cells in the skin of the amphibian Xenopus laevis | |
CN115369112B (zh) | 去内毒素质粒提取用结合液及试剂盒及质粒提取方法 | |
CN114774337B (zh) | 一种基于工程大肠杆菌的HCoV-229E病毒检测系统 | |
CN114774425B (zh) | 一种基于工程大肠杆菌的MERS-CoV病毒检测系统 | |
JP6811725B2 (ja) | 組換えタンパク質の生成方法 | |
Song et al. | Oxalate induces the ossification of RTECs by activating the JAK2/STAT3 signaling pathway and participates in the formation of kidney stones | |
Sakurai et al. | TSC22D4 promotes TGFβ1-induced activation of hepatic stellate cells | |
EP3759494A1 (en) | Engineered immune cells as diagnostic probes of disease | |
WO2018024153A1 (zh) | 重组猪瘟e2蛋白及其亚单位疫苗的制备方法和应用 | |
CN112501192B (zh) | 产生抗人il21单克隆抗体的杂交瘤细胞株及其应用 | |
CN112921046A (zh) | 一种可溶性人肿瘤坏死因子ⅱ型受体蛋白的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |